Related Experiment Videos
In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A)
B P Goldstein1, M Berti, F Ripamonti
1Lepetit Research Center, Marion Merrell Dow Research Institute, Gerenzano, Varese, Italy.
Abstract:
MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.
Insights
A novel peptide antibiotic, MDL 62,879, effectively inhibits protein synthesis and shows potent activity against resistant gram-positive bacteria and Mycobacterium tuberculosis.
Area of Science:
- Microbiology
- Molecular Biology
- Pharmacology
Background:
- The rise of antibiotic resistance necessitates the development of new antimicrobial agents.
- Peptide antibiotics offer a promising avenue for novel therapeutic strategies.
- Elongation factor Tu is a validated target for protein synthesis inhibition.
Purpose of the Study:
- To characterize the antimicrobial activity and mechanism of action of MDL 62,879 (GE2270 A).
- To evaluate the efficacy of MDL 62,879 against clinically relevant resistant pathogens.
Main Methods:
- Minimum Inhibitory Concentration (MIC) determination against clinical isolates.
- Testing against multidrug-resistant strains.
- Assessment of activity against Mycobacterium tuberculosis.
- Evaluation of bactericidal activity.
Main Results:
- MDL 62,879 demonstrated high activity against Gram-positive bacteria, including staphylococci and enterococci (MIC90 <= 0.13 µg/ml).
- The compound was effective against isolates resistant to multiple antibiotic classes (beta-lactams, erythromycin, gentamicin, glycopeptides).
- Activity was also observed against Mycobacterium tuberculosis, with moderate bactericidal effects on staphylococci.
Conclusions:
- MDL 62,879 is a potent peptide antibiotic targeting bacterial protein synthesis via elongation factor Tu.
- Its broad spectrum of activity, including against resistant strains, makes it a promising candidate for further development.